Systemic Administration of the Immunophilin Ligand GPI 1046 in MPTP-Treated Monkeys

By Emborg M.E.   Shin P.   Roitberg B.   Sramek J.G.   Chu Y.   Stebbins G.T.   Hamilton J.S.   Suzdak P.D.   Steiner J.P.   Kordower J.H.  

Experimental Neurology, Vol. 168, Iss. 1, 2001-03 ,pp. : 171-182

Elsevier

Access to resources Recommend Favorite

[ 125 I]EGF Binding in Basal Ganglia of Patients with Parkinson's Disease and Progressive Supranuclear Palsy and in MPTP-Treated Monkeys

By Villares J.   Faucheux B.   Herrero M.T.   Obeso J.A.   Duyckaerts C.   Hauw J.-J.   Agid Y.   Hirsch E.C.  

Experimental Neurology, Vol. 154, Iss. 1, 1998-11 ,pp. : 146-156

Elsevier

Access to resources Recommend Favorite

Spontaneous Blink Rates Correlate with Dopamine Levels in the Caudate Nucleus of MPTP-Treated Monkeys

By Taylor J.R.   Elsworth J.D.   Lawrence M.S.   Sladek J.R.   Roth R.H.   Redmond D.E.  

Experimental Neurology, Vol. 158, Iss. 1, 1999-07 ,pp. : 214-220

Elsevier

Access to resources Recommend Favorite

Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys

By Wallace Bradley A.  

Brain, Vol. 130, Iss. 8, 2007-08 ,pp. : 2129-2145

Oxford University Press

Access to resources Recommend Favorite

Combined Use of the Adenosine A 2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys

By Kanda T.   Jackson M.J.   Smith L.A.   Pearce R.K.B.   Nakamura J.   Kase H.   Kuwana Y.   Jenner P.  

Experimental Neurology, Vol. 162, Iss. 2, 2000-04 ,pp. : 321-327

Elsevier

Access to resources Recommend Favorite